Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Wednesday, October 28, 2026

⚡ Executive Takeaway

Three autoimmune cell therapy programs have hit safety walls since August, and the detail that matters tonight is where the one assessed cause landed: on fludarabine, the decades old conditioning chemotherapy, not on the cells. Lymphodepletion is the shared backbone across most of the modality, autologous and allogeneic alike, so every sponsor in the field inherited this liability the day it wrote a protocol, and Artiva publishing the case will put a mechanism on a risk the field has treated as routine plumbing. The strategic consequence runs one way: therapies that deplete B cells without conditioning, the bispecific T cell engagers now crowding into lupus and myositis, just had their core selling point written for them by a competitor's 8-K. Watch three things from here: ACR Convergence in the coming weeks for where rheumatologists land, whether Bristol and Novartis touch their conditioning regimens on any restart, and whether allogeneic durability, the reason Artiva actually gave for killing the program, shows up as a problem in the next off the shelf dataset.

The cross program safety table, the SAFFRON subsets, the Novartis quarter and the movers, all below. 👉 Read Full Analysis

🧬 The Cell Therapy Bet Unwinds

Artiva killed AlloNK, canceled its Phase 3, and cut 94% of its staff, and the one death with an assessed cause traces to the conditioning chemotherapy, not the cells. ARTV | BMY | NVS

The company's own release is blunt: responses did not last long enough to clear its bar, and two Grade 5 events sat on top. One, a leukoencephalopathy death after cyclophosphamide and fludarabine conditioning, was assessed by the investigator and an independent review as likely fludarabine neurotoxicity; the second, a sudden death about two months into treatment, is undetermined and assessed as unrelated to the regimen. The FDA paused the Phase 2a and Artiva pulled the Phase 3 itself. What remains is $319.1 million in preliminary cash, a Leerink run process the release says may end in a merger, asset sales or liquidation, and a canceled ACR presentation. Shares closed at 4.27, down 30.7%, our arithmetic on settled closes. The field's 2026 scorecard, context rows per BioPharma Dive:

🫁 The All Oral Answer to Tagrisso Resistance

SAFFRON put a 4.9 month survival gain in The New England Journal of Medicine and makes MET testing at osimertinib progression the default workup. AZN | HCM

The numbers, from AstraZeneca's release: progression free survival 7.6 versus 5.4 months (hazard ratio 0.55) and overall survival 17.8 versus 12.9 months (0.68) against platinum chemotherapy, in 338 patients whose EGFR mutated tumors developed MET overexpression or amplification after osimertinib. Severe adverse events matched chemotherapy, 64 versus 63%, with more than double the time on treatment. The US NDA went in late September, China has already approved the combination, and about a third of tumors take this resistance route by HUTCHMED's estimate, so the operational consequence lands on diagnostics: MET testing by IHC and FISH at progression stops being optional. The data ran Sunday at the Presidential Symposium; our weekend sweep missed it, and we print it here dated.

💰 Novartis Pays for the Miss and Raises the Year

A $1.9 billion writedown on del-desiran landed in the same quarter Novartis raised its core operating income guidance. NVS

Sales grew 4% in constant currencies to $14.5 billion and core operating income grew 10%, with Kisqali up 37%, Scemblix up 67% and Leqvio up 63%, per Tuesday's results materials. The impairment covers the lead asset from the $12 billion Avidity acquisition after September's HARBOR miss, and the remaining $5.5 billion carrying value is itself a statement: Novartis told investors it stands by the deal. The quieter headlines are remibrutinib, headed to the FDA this quarter with a priority review voucher after two positive multiple sclerosis Phase 3 trials, and Rhapsido peak sales guidance moving above $4 billion. Franchise defense is expensive; this is what it looks like when the base business can absorb it.

🎗️ ADC Week Ends on Its Two Tails

BioNTech's trastuzumab pamirtecan won its Phase 3 and may still be shelved, while Hansoh's Ris-Rez cut progression risk 67% where nothing is approved at all. BNTX | GSK

DYNASTY-Breast02 met its endpoint in 541 patients with hormone receptor positive, HER2 low metastatic breast cancer, and the sponsors' own Monday release calls the improvement modest, the potential benefit limited, and interstitial lung disease higher than in prior trials, with no figures disclosed and next steps under discussion. Against an incumbent like Enhertu, a statistical win over chemotherapy is not a product. The other tail: in relapsed osteosarcoma, Hansoh's B7-H3 ADC posted 5.5 versus 1.4 months of progression free survival, hazard ratio 0.33, per trade reports of the ESMO presentation, with 93% Grade 3 plus treatment related events at the higher, bone penetrating dose. A China filing is planned and GSK holds rights everywhere else with FDA breakthrough designation in hand. Same modality, same week: the setting, not the molecule, decides the value.

⚖️ Lilly's Comparison Ads Survive

A federal judge refused to pull Lilly's head to head obesity campaign on Monday, and the reasoning reads like a manual for comparative claims. LLY | NVO

Judge Zahid Quraishi denied Novo Nordisk's preliminary injunction because the harm never showed: Wegovy prescriptions held flat while the ads ran, the ads acknowledged the newer high dose Wegovy, and Lilly had already softened its Zepbound spots after a cease and desist letter, per BioPharma Dive. He also noted Novo's own Ozempic ads claimed superiority over Trulicity without dose context. The merits case continues, but comparative advertising now runs uninterrupted through the obesity market's biggest commercial stretch, and the practical bar for silencing a rival's trial based claims is visibly high.

🧫 Ferring Buys the Three Day IVF Cycle

Gameto's Fertilo, stem cell derived ovarian support cells that mature eggs outside the body, drew up to $1.38 billion from the quietest big buyer in fertility. Ferring and Gameto are private

The deal, announced Tuesday, is reported at up to $1.38 billion by Endpoints News, with BioPharma Dive rounding to $1.4 billion; the upfront is undisclosed and the balance is development, regulatory and sales milestones. Fertilo's pitch is operational: eggs matured outside the body instead of roughly two weeks of hormone injections, compressing IVF and egg freezing cycles to as little as three days by the company's account. It is cleared in Australia and parts of Latin America with a US Phase 3 running, so Ferring is buying a regulatory bet it already has the commercial infrastructure to exploit. Gameto had raised $127 million since 2020, which makes the headline number roughly ten times invested capital, our arithmetic, and a marker for how scarce late stage women's health assets have become.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →